Medexus Pharmaceuticals (TSE:MDP) Price Target Raised to C$4.50

Medexus Pharmaceuticals (TSE:MDP) had its price objective raised by equities research analysts at Stifel Nicolaus from C$4.15 to C$4.50 in a research report issued on Tuesday,BayStreet.CA reports. Stifel Nicolaus’ target price would indicate a potential upside of 2.51% from the stock’s current price.

A number of other equities analysts also recently commented on MDP. Raymond James upgraded Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective for the company in a report on Wednesday, January 8th. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Finally, Leede Financial set a C$8.25 price objective on Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a research note on Monday, September 30th. Two analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Medexus Pharmaceuticals presently has a consensus rating of “Strong Buy” and a consensus price target of C$5.58.

Medexus Pharmaceuticals Stock Up 3.3 %

Shares of TSE:MDP traded up C$0.14 during mid-day trading on Tuesday, reaching C$4.39. 45,478 shares of the stock were exchanged, compared to its average volume of 95,070. The stock’s 50 day simple moving average is C$2.84 and its 200-day simple moving average is C$2.57. Medexus Pharmaceuticals has a one year low of C$1.47 and a one year high of C$4.40. The company has a market cap of C$107.69 million, a P/E ratio of 87.80 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.